Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0MGRBJ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
HER2-ADC-007
|
|||||
| Synonyms |
HER2-ADC-007
Click to Show/Hide
|
|||||
| Organization |
Suzhou Medilink Therapeutics Ltd.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1.93;5.85
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
DL012-payload
|
Payload Info | ||||
| Payload Name |
DL003-payload
|
Payload Info | ||||
| Linker Name |
DL012-Linker
|
Linker Info | ||||
| Linker Name |
DL003-Linker
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
DL012;DL003
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
90.18%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (BALB/C),by subcutaneous injection of 5x106 (NCI-H358) tumor cells, and treatment with 1mg/kg (QWƧ) ADC after tumor volume about 200mm3. Determined tumor volume after the experiment, measured at day 29.
|
||||
| In Vivo Model | NCI-H358 xenograft model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
90.99%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (BALB/C),by subcutaneous injection of 5x106 (NCI-H358) tumor cells, and treatment with 3mg/kg (QWƧ) ADC after tumor volume about 200mm3. Determined tumor volume after the experiment, measured at day 29.
|
||||
| In Vivo Model | NCI-H358 xenograft model | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
95.80%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (BALB/C),by subcutaneous injection of 5x106 (NCI-H358) tumor cells, and treatment with 10mg/kg (QWƧ) ADC after tumor volume about 200mm3. Determined tumor volume after the experiment, measured at day 29.
|
||||
| In Vivo Model | NCI-H358 xenograft model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.02 nM | Low her2 expression (her2+) | ||
| Method Description |
MCF7, 5000cell/well were plated at set initial densities in 96 well flat bottom plates in the appropriate growth media. 24 hours later, dosing solutions were added, the maximum concentration of the drug is 2000 nM with a 4-fold dilution across 10 points, for the various ADCs. Cell proliferation was measured after 4 days exposure, 50ul Cell titer glo to test IC50.
Click to Show/Hide
|
||||
| In Vitro Model | Invasive breast carcinoma | MCF-7 cells | CVCL_0031 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.02 nM | Positive her2 expression (her2+++/++) | ||
| Method Description |
NCIN87 HABCG2, 3000cell/well were plated at set initial densities in 96 well flat bottom plates in the appropriate growth media. 24 hours later, dosing solutions were added, the maximum concentration of the drug is 200 nM with a 5-fold dilution across 10 points, for the various ADCs. Cell proliferation was measured after 6 days exposure, 75ul Cell titer glo to test IC50.
Click to Show/Hide
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.04 nM | Positive her2 expression (her2+++/++) | ||
| Method Description |
NCI N87 5000cell/well were plated at set initial densities in 96 well flat bottom plates in the appropriate growth media. 24 hours later, dosing solutions were added, the maximum concentration of the drug is 1000 nM with a 4-fold dilution across 10 points, for the various ADCs. Cell proliferation was measured after 4 days exposure, 50ul Cell titer glo to test IC50.
Click to Show/Hide
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.04 nM | High her2 expression (her2 +++) | ||
| Method Description |
SKBR3, 5000cell/well were plated at set initial densities in 96 well flat bottom plates in the appropriate growth media. 24 hours later, dosing solutions were added, the maximum concentration of the drug is 2000 nM with a 4-fold dilution across 10 points, for the various ADCs. Cell proliferation was measured after 4 days exposure, 50ul Cell titer glo to test IC50.
Click to Show/Hide
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.65 nM | Low her2 expression (her2+) | ||
| Method Description |
H358, 5000cell/well were plated at set initial densities in 96 well flat bottom plates in the appropriate growth media. 24 hours later, dosing solutions were added, the maximum concentration of the drug is 2000 nM with a 4-fold dilution across 10 points, for the various ADCs. Cell proliferation was measured after 4 days exposure, 50ul Cell titer glo to test IC50.
Click to Show/Hide
|
||||
| In Vitro Model | Minimally invasive lung adenocarcinoma | H358 cells | CVCL_1559 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 1.85 nM | Positive her2 expression (her2+++/++) | ||
| Method Description |
NCI N87, 2000cell/well were plated at set initial densities in 96 well flat bottom plates in the appropriate growth media. 24 hours later, dosing solutions were added, the maximum concentration of the drug is 300 nM with a 4-fold dilution across 10 points, for the various ADCs. Cell proliferation was measured after 6 days exposure, 75ul Cell titer glo to test IC50.
Click to Show/Hide
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 54.6 nM | Positive her2 expression (her2+++/++) | ||
| Method Description |
NCIN87 HABCB1, 3000cell/well were plated at set initial densities in 96 well flat bottom plates in the appropriate growth media. 24 hours later, dosing solutions were added, the maximum concentration of the drug is 2000 nM with a 5-fold dilution across 10 points, for the various ADCs. Cell proliferation was measured after 6 days exposure, 75ul Cell titer glo to test IC50.
Click to Show/Hide
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||